Celgene Corp. Company Profile (NASDAQ:CELG)

Analyst Ratings

Consensus Ratings for Celgene Corp. (NASDAQ:CELG) (?)
Ratings Breakdown: 4 Hold Rating(s), 22 Buy Rating(s)
Consensus Rating:Buy (Score: 2.85)
Consensus Price Target: $139.09 (23.95% upside)

Analysts' Ratings History for Celgene Corp. (NASDAQ:CELG)
Show:
DateFirmActionRatingPrice TargetActions
7/28/2016Piper Jaffray Cos.Set Price TargetBuy$145.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/28/2016Cowen and CompanyReiterated RatingBuy$150.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/26/2016Robert W. BairdReiterated RatingOutperform$162.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/26/2016BMO Capital MarketsReiterated RatingBuy$141.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/26/2016RBC Capital MarketsReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/26/2016Jefferies GroupReiterated RatingBuy$138.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/20/2016JPMorgan Chase & Co.Set Price TargetBuy$136.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/17/2016Canaccord GenuityReiterated RatingOutperform$156.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/14/2016Stifel NicolausInitiated CoverageBuy$138.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/12/2016Credit Suisse Group AGReiterated RatingOutperform$140.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/6/2016JMP SecuritiesReiterated RatingBuy$152.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/5/2016Leerink SwannReiterated RatingHold$125.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/30/2016Morgan StanleyReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2016Barclays PLCReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016Cantor FitzgeraldReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016Bank of America Corp.Reiterated RatingBuy$125.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2016BTIG ResearchDowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/25/2016William BlairReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/18/2016ArgusReiterated RatingBuy$155.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/28/2016Raymond James Financial Inc.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/28/2016SunTrust Banks Inc.Reiterated RatingBuy$145.00 -> $147.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2016Citigroup Inc.Initiated CoverageBuy$130.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016Goldman Sachs Group Inc.Lower Price Target$90.00 -> $83.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/29/2016Royal Bank Of CanadaLower Price TargetOutperform$150.00 -> $135.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/22/2016Wells Fargo & Co.Reiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/14/2016Standpoint ResearchInitiated CoverageBuy$130.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/25/2015NomuraReiterated RatingBuy$165.00 -> $167.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/15/2015Deutsche Bank AGBoost Price TargetBuy$160.00 -> $175.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/2/2015Sanford C. BernsteinReiterated RatingBuy$154.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/30/2015S&P Equity ResearchReiterated RatingStrong-BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for Celgene Corp. (NASDAQ:CELG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/28/2016        
7/28/2016Q216$1.39$1.44$2.70 billion$2.74 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/28/2016Q116$1.29$1.32$2.59 billion$2.51 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/28/2016Q415$1.22$1.18$2.54 billion$2.54 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315$1.22$1.23$2.40 billion$2.33 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/23/2015Q215$1.08$1.23$2.24 billion$2.28 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q115$1.06$1.07$2.11 billion$2.08 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/29/2015Q414$0.99$1.01$2.08 billion$2.09 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/23/2014Q314$0.95$0.97$1.96 billion$1.96 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/24/2014Q214$0.89$0.90$1.85 billion$1.87 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/24/2014Q114$1.65$1.67$1.77 billion$1.71 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/30/2014Q413$1.54$1.51$1.72 billion$1.76 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/24/2013Q313$1.54$1.56$1.64 billion$1.67 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/25/2013Q2 2013$1.44$1.52$1.54 billion$1.56 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/25/2013Q1 2013$1.35$1.37$1.47 billion$1.43 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/24/2013Q4 2012$1.31$1.32$1.45 billion$1.42 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/25/2012$1.26$1.29ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/26/2012$1.19$1.22ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/26/2012$1.13$1.08ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/26/2012$1.06$1.05ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/27/2011$0.95$1.02ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/28/2011$0.85$0.89ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/28/2011$0.80$0.83ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/27/2011$0.73$0.73ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Celgene Corp. (NASDAQ:CELG)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$1.09$1.09$1.09
Q2 20162$1.25$1.26$1.26
Q3 20162$1.28$1.32$1.30
Q4 20162$1.35$1.39$1.37
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Celgene Corp. (NASDAQ:CELG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Celgene Corp. (NASDAQ:CELG)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/20/2016Robert J HuginInsiderSell75,000$100.16$7,512,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/4/2016Gilla KaplanDirectorSell15,967$101.84$1,626,079.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2016Michael W BonneyDirectorBuy2,000$103.01$206,020.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/22/2016James J LoughlinDirectorSell2,100$104.12$218,652.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/28/2015Ernest MarioDirectorSell40,000$119.36$4,774,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2015Michael D CaseyDirectorSell20,000$122.11$2,442,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/21/2015Gilla KaplanDirectorSell14,464$110.62$1,600,007.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2015Gilla KaplanDirectorSell15,000$122.45$1,836,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015Michael D. CaseyDirectorSell15,000$121.76$1,826,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/13/2015Thomas O DanielInsiderSell30,156$120.78$3,642,241.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2015Gilla KaplanDirectorSell15,000$111.74$1,676,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2015Michael D CaseyDirectorSell15,000$111.18$1,667,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2015Gilla KaplanDirectorSell15,000$122.89$1,843,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/6/2015Mark J AllesInsiderSell117,099$120.68$14,131,507.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2015Lawrence V SteinInsiderSell26,666$120.01$3,200,186.66View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015Gilla KaplanDirectorSell45,536$113.47$5,166,969.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2014Gilla KaplanDirectorSell15,000$118.20$1,773,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014Robert J HuginInsiderSell158,000$106.68$16,855,440.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/27/2014Ernest MarioDirectorSell100,000$102.85$10,285,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/24/2014Michael D CaseyDirectorSell15,000$102.94$1,544,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2014Gilla KaplanDirectorSell30,000$93.73$2,811,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/4/2014Perry A KarsenInsiderSell39,104$87.55$3,423,555.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/25/2014Richard W BarkerDirectorSell17,600$87.03$1,531,728.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014Perry KarsenInsiderSell11,922$146.78$1,749,911.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2014Michael CaseyDirectorSell12,770$162.33$2,072,954.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/5/2014Ernest MarioDirectorSell13,500$151.87$2,050,245.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2013Lawrence SteinInsiderSell12,062$168.19$2,028,707.78View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/25/2013Carrie Smith CoxDirectorSell18,750$157.67$2,956,312.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2013Gilla KaplanDirectorSell15,000$143.92$2,158,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2013Thomas DanielInsiderSell32,263$137.06$4,421,966.78View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/2/2013Perry A KarsenInsiderSell93,008$146.50$13,625,672.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/30/2013Robert J HuginInsiderSell68,087$123.58$8,414,191.46View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2013Ernest MarioDirectorBuy1,000$123.72$123,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/28/2013Thomas O DanielInsiderSell32,959$124.91$4,116,908.69View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Celgene Corp. (NASDAQ:CELG)
DateHeadline
07/30/16 12:01 PMCelgene revenue rises on higher demand for flagship drug Revlimid
07/30/16 12:01 PMBiondo Investment Advisors Lowers stake in Celgene Corporation (CELG)
07/29/16 08:32 AMCelgene Corporation Nails the Second Quarter - After a strong start to the year, the biotech increased its full-year earnings guidance.
07/28/16 10:21 PMWhat Are Analysts Saying About Q2 at Biotech's Big 4? Amgen, Biogen, Celgene, Gilead - Second-quarter earnings season has been going for more than a week, and we’ve had a chance to hear from all four of the biggest companies in biotech as measured by sales, market valuation and clout. Here’s what they had to say in their business updates, along with some commentary from analysts [...]
07/28/16 09:48 PMCelgene Corporation (CELG) Pops 2.91% for July 28 - Equities.com
07/28/16 09:48 PMCelgene Raises Guidance as Sales of Top Drug Revlimid Grow (2)
07/28/16 09:48 PMCelgene Takes Over #52 Spot From Boeing
07/28/16 09:48 PMCelgene Corporation (CELG) Pops 2.91% for July 28
07/28/16 05:28 PMStock Indexes Add Tiny Gains, But Biotech Celgene Rockets; Is It Time To Buy? - Stocks crawled higher on Thursday amid another deluge of quarterly results. But Celgene raised hopes for biotech investors with a strong gain following robust second-quarter results.
07/28/16 04:01 PMCelgene's Otezla Is A Big Hit - Otezla demand has this drug on pace to achieve billion dollar blockbuster status this year.
07/28/16 02:42 PMThis Small Gain Is a Big Win for Celgene Corporation - Forget about Revlimid -- this drug was Celgene's standout drug in the second quarter.
07/28/16 02:04 PMCelgene Is Heading Even Higher -- Here's How to Trade It Now -
07/28/16 11:55 AMCelgene Reports Second Quarter 2016 Operating and Financial Results
07/28/16 11:55 AMCelgene Raises Guidance as Sales of Top Drug Revlimid Grow (1)
07/28/16 11:55 AMCelgene Lifts Guidance as Revlimid Sales Rise
07/28/16 11:55 AMCelgene (CELG) Beats on Q2 Earnings and Revenues
07/28/16 11:55 AMSales of flagship drug Revlimid drive Celgene profit; forecast raised
07/28/16 11:33 AMCelgene Beats Estimates, Raises Earnings Outlook -
07/28/16 11:28 AMJim Cramer Says Oncology Drug Franchises Helping Both Celgene and Bristol-Myers -
07/28/16 11:11 AMCelgene (CELG) Tops Q2 Earnings & Revenues, Lifts View -
07/28/16 10:14 AMCelgene: Doing What Amgen and Gilead Couldn't -
07/28/16 08:45 AMCelgene Reports Second-Quarter Results, Highlights 'Outstanding' 2016 Performance - Shares of Celgene Corporation (NASDAQ: CELG) were trading higher by 0.43 percent at $108.11 after the company reported its second-quarter results. Celgene said it earned $1.44 per share in the second quarter on revenue of $2.74 billion. Wall Street analysts were expecting the company to earn $1.39 per share on revenue of $2.7 billion. Net income for the quarter on a GAAP basis rose to $598 million from $356 million in the same quarter a year ago as the company benefited from a sales growth of 22 percent. Related Link: Biotech In The Earnings Spotlight: Amgen, Celgene, Gilead Sciences Celgene also raised its ...Full story available on Benzinga.com
07/28/16 08:25 AMHow Celgene Won With This Earnings Report -
07/27/16 08:54 PMSee Which Of The Latest 13F Filers Holds Celgene
07/27/16 08:54 PMCelgene Corporation's (NASDAQ:CELG) Revlimid Fails to Achieve $1 Billion Boost
07/27/16 08:54 PMDrug Giant Could Help Boost Biotech ETF Rally
07/27/16 08:54 PMCelgene Corporation (NASDAQ:CELG) Revlimid Jeopardizes Its $1 Billion Hope
07/27/16 02:25 PMBiotech Stock Roundup: Biogen Q2 Results Impress, Gilead HCV Franchise Under Pressure -
07/27/16 11:42 AMNotable Brokerage Recommendations: Celgene Corporation (NASDAQ:CELG), Bank of New York Mellon Corp (NYSE ... - Review Fortune
07/26/16 09:08 PMCelgene Drug Misses Secondary Endpoint in One of Its Lymphoma Trials
07/26/16 09:08 PMMarket Update: Celgene Corporation (NASDAQ:CELG) – Celgene drug fails to extend survival in lymphoma study
07/26/16 03:39 PMCelgene Slides After Deciding Against Revlimid Label Expansion -
07/26/16 01:33 PM3 Things to Watch as Celgene Corporation Reports Earnings - Increasing Revlimid sales is key, but don't forget about Otezla.
07/26/16 11:15 AMMarket Update: Celgene Corporation (NASDAQ:CELG) - Celgene drug fails to extend survival in lymphoma study - Jutia Group (press release) (blog)
07/26/16 11:15 AMAnalysts and Technical Update on Celgene Corp (NASDAQ:CELG) - Street Report
07/26/16 09:34 AMWhy Gilead Can't Easily Copy Celgene's 'Partner Partner Partner' Deal-Making Playbook -
07/26/16 09:30 AMCelgene: So Much For That Buying Opportunity -
07/25/16 07:51 PMNotable Research Reports: Mattel, Inc. (NASDAQ:MAT), Celgene Corporation (NASDAQ:CELG) - Review Fortune
07/25/16 07:51 PMCelgene (CELG), LYSA Announce Initial REVLIMID Phase 3 Data in DLBCL; Primary Endpoint was Achieved
07/25/16 07:51 PMCelgene shares slide after Revlimid use expansion curbed
07/25/16 07:51 PMCelgene : Drug Misses Secondary Endpoint in One of Its Lymphoma Trials
07/25/16 05:57 PMLate-stage study of Celgene's Revlimid as maintenance therapy in certain lymphoma patients fails to boost overall survival; development plans for the indication nixed; shares off 3% after hours -
07/25/16 05:08 PMCelgene Falls After Blockbuster Cancer Drug Revlimid Fails To Extend Survival -
07/25/16 04:30 PMCelgene drug fails to extend survival in lymphoma study - [Reuters] - Celgene Corp said on Monday that its flagship drug Revlimid failed to extend survival as a maintenance therapy for a type of blood cancer after patients had responded to prior treatment. As a result, the U.S. biotechnology company said it would not seek an additional approval for Revlimid for that use, and its shares fell more than 2 percent. Revlimid, a multiple myeloma treatment with annual sales of about $6 billion, was being tested versus a placebo in patients whose diffuse large B-cell lymphoma had responded to initial treatment with Roche's Rituxan and chemotherapy.
07/25/16 04:06 PMCelgene Can't Expand Revlimid Approval Into Non-Hodgkin Lymphoma Just Yet -
07/25/16 02:23 PMCelgene (CELG) Q2 Earnings: Can the Stock Pull a Surprise?
07/22/16 03:11 PMCelgene Corporation (CELG) Pops 2.71% for July 21 - Equities.com
07/22/16 11:18 AMCommit To Purchase Celgene Corp. At $55, Earn 3.4% Using Options
07/22/16 11:00 AMCelgene (CELG) Stock Is the 'Chart of the Day' -
07/21/16 08:42 PMClass Fee In $7.2B Receptos Merger Suit Slashed To $100K

Social

About Celgene Corp.

Celgene Corp. logoCelgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company's primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin). The Company's clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: CELG
  • CUSIP: 15102010
Key Metrics:
  • Previous Close: $111.26
  • 50 Day Moving Average: $102.41
  • 200 Day Moving Average: $103.04
  • P/E Ratio: 47.42
  • P/E Growth: 0.89
  • Market Cap: $87.69B
  • Beta: 1.21
  • Current Year EPS Consensus Estimate: $5.06 EPS
  • Next Year EPS Consensus Estimate: $6.31 EPS
Additional Links:
Celgene Corp. (NASDAQ:CELG) Chart for Saturday, July, 30, 2016